Tech Company Financing Transactions

Pulmocide Funding Round

SR One Capital Management, F-Prime Capital and Johnson & Johnson Development Corporation participated in a $30 million Series B funding round for Pulmocide. The financing round was announced on 3/22/2017.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

44 Southampton Buildings
London, WC2A 1AP
UK

Phone

+44 203 763 9484

Website

www.pulmocide.com

Email Address

[email protected]

Overview

Pulmocide is a privately-held company located in London, developing novel small molecule inhaled medicines for the treatment of life threatening respiratory infections caused by RSV and Aspergillus.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Daniel Burgess

        

Chief Medical Officer

Lance Berman

        

Chief Scientific Officer

Pete Strong

        

VP - Bus. Development

Jennifer Cayer

        

VP - Operations

David Mantus

        

Browse more venture capital transactions:

Prev: 3/22/2017: Shipt venture capital transaction
Next: 3/22/2017: RavenPack venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to document every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary